Tofacitinib (Xeljanz) was associated with increases in serum lipid levels among patients with psoriatic arthritis (PsA), according to the findings of a recent study.
In the study, the researchers pooled data from 2 phase 3 studies and 1 ongoing long-term extension study, which included a total of 783 participants treated with tofacitinib. They assessed fasting lipid levels, blood pressure, hypertension-related adverse events (AD), and major cardiovascular events (MACE).
You may also like...
Supporting Combined Clinics to Improve PsA Care
Do Comorbidities Affect Physical Function in PsA?
They found percentage increases from baseline in low-density and high-density lipoprotein cholesterol levels (LDL and HDL) ranged from 9% to 14% for 5 mg and 10 mg doses of tofacitinib at 3 and 6 months. However, they did not observe any meaningful changes in LDL/HDL or total cholesterol/HDL ratios. Blood pressure remained stable through 24 months, the researchers said.
Overall, 58 participants (7.4%) had hypertension-related adverse events; however, none were fatal. Five participants (0.6%) experienced a MACE; 2 died.
“Serum lipid level increases at month 3 following tofacitinib treatment in PsA were consistent with observations in rheumatoid arthritis and psoriasis,” the researchers concluded. “The incidence rate of hypertension‐related AEs and MACE was low; long‐term follow‐up is ongoing.”
Gladman DD, Charles‐Schoeman C, McInnes IB, et al. Changes in lipid levels and incidence of cardiovascular events following tofacitinib treatment in patients with psoriatic arthritis: A pooled analysis across phase 3 and long‐term extension studies [published online May 21, 2019]. Arthritis Care Res. doi:10.1002/acr.23930